What question did this study set out to answer?

The study investigates how MED30 amplification affects MYC binding to low-affinity enhancers and its implications in cancer progression.

June 14, 2026Cell ReportsOpen Access

Amplification of MED30 at chromosome 8q24 reprograms MYC binding to low-affinity oncogenic enhancers in cancer cells

View Full Paper

Ask AI

Bookmark

The study investigates how MED30 amplification affects MYC binding to low-affinity enhancers and its implications in cancer progression.
Investigated MED30 amplification and MYC binding in pancreatic ductal adenocarcinoma and glioblastoma.
Conducted functional studies to analyze the impact of MED30 on gene expression and MYC occupancy.
Assessed MED30 as a prognostic marker independent of MYC amplification.
MED30 amplification is associated with increased MYC binding to low-affinity regulatory regions.
Overexpression of MED30 enables MYC occupancy of previously weak enhancers, driving tumor-promoting gene expression.
Functional studies confirm MED30 as an oncogenic factor and prognostic marker.

No takes yet. Share an insight, caveat, or question.

Randomized trial demonstrates MED30's role in enhancing MYC binding to oncogenic sites, indicating its potential as a prognostic marker.

Jin et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark